Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells
- Development stage
- Phase 2
- Lead developer
- Chinese PLA General Hospital
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells** is a nonproprietary trial-intervention descriptor rather than a uniquely named cell-therapy asset. It refers to allogeneic, CRISPR-Cas9 gene-edited universal CAR-T-cell products designed to recognize CD19 together with either CD20 or CD22 on malignant B cells. The dual-antigen strategy is intended to reduce relapse driven by loss of CD19 expression after CD19-directed CAR-T therapy. The registered Phase I/II study sponsored by Chinese PLA General Hospital evaluates feasibility, safety, in-vivo persistence, and antitumor activity in relapsed or refractory B-cell leukemia and B-cell lymphoma. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03398967?tab=table))
- Other names
- Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells.